Phase 2
N=64
Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery
Thromboembolism
Bottom Line
View on ClinicalTrials.gov: NCT06118957 ↗Enrolled (actual)
64
Serious AEs
0.0%
Results posted
Sep 2025
Primary outcome: Primary: Rate of Eligible Individuals Enrolled and Retained Through Full Study Procedures — 694; 611; 64; 61 participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Enoxaparin (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- University of Utah
- Primary completion
- Jul 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Rate of Eligible Individuals Enrolled and Retained Through Full Study Procedures |
694; 611; 64; 61 | — |
| SECONDARY Rate of Venous Thromboembolism |
0; 0 | — |
| SECONDARY Rate of Wound Hematoma or Infection |
2; 1 | — |
| SECONDARY Rate of Bleeding Complications |
0; 1 | — |
Summary
The aim of this study is to evaluate the feasibility of randomizing individuals to low molecular weight heparin (enoxaparin) or no treatment following cesarean delivery. The investigators hypothesize that among eligible individuals, at least 35% will enroll, undergo randomization, and complete the allocated treatment group.
Eligibility Criteria
Inclusion Criteria
- Cesarean delivery at the University of Utah Health
Exclusion Criteria
- Contraindication to anticoagulation
- Plan for therapeutic anticoagulation
- Known renal dysfunction (creatinine clearance 2 weeks
Data sourced from ClinicalTrials.gov (NCT06118957). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.